Moderna wins EU recommendation for updated COVID shot
hapabapa

Moderna (NASDAQ:MRNA) announced Thursday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), adopted a positive opinion on its latest COVID-19 vaccine, recommending its marketing authorization for the region.
The decision paves the way for the EU authorities to add the vaccine, adjusted for the Omicron XBB.1.5 variant, for the region's autumn/winter 2023 immunization campaign, subject to final authorization from the European Commission.

The recommendation is to allow the vaccine branded as Spikevax to be used for active immunization against COVID-19 in those aged six months and older, the company said.

In clinical studies, the messenger-RNA-based vaccine has shown efficacy against XBB.1.5, XBB.1.16, and XBB.2.3.2 variants of Omicron, as well as the highly mutated BA.2.86 variant, also known as Pirola.



More on Moderna

Seeking Alphaâs Quant Rating on Moderna
Historical earnings data for Moderna
Financial information for Moderna
Moderna, Inc. R&D Day and Business Updates (Transcript)
Moderna, Inc. Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)
Pfizer, Moderna And COVID Vaccine Patents: Implications Of Legal Cases
Moderna: Buy Before The Fall Covid-19 Wave
Barclays projects over $5B COVID booster sales in fall 2023
Biggest stock movers today: Grab Holdings, Workhorse Group, Rocket Pharmaceuticals and more
Moderna sees $10B â $15B sales from launching new products by 2028
CDC recommends COVID-19 shots for people age six months and older (update)